NRD
UTHR icon

Nebula Research & Development’s United Therapeutics UTHR Stock Holding History

Nebula Research & Development’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,356
Closed -$964K – 831
2025
Q2 		$964K Buy
3,356
+645
+24% +$193K 0.08% 411
2025
Q1 		$836K Sell
2,711
-1,873
-41% -$642K 0.08% 429
2024
Q4 		$1.62M Buy
+4,584
New +$1.68M 0.19% 159
2024
Q1 		– Sell
-2,997
Closed -$659K – 1008
2023
Q4 		$659K Buy
2,997
+65
+2% +$15K 0.2% 160
2023
Q3 		$662K Buy
+2,932
New +$675K 0.35% 75

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Nebula Research & Development's UTHR Position: Q3 2025 in Review

Nebula Research & Development sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 3,356 shares — an estimated $964K sold.

Nebula Research & Development first reported a position in UTHR in Q3 2023 and held it in 5 quarters. The position peaked at $1.62M in Q4 2024. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Nebula Research & Development reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 3,356 United Therapeutics shares in Q3 2025, an estimated $964K.
  • Nebula Research & Development first reported a position in United Therapeutics in Q3 2023 and held it in 5 quarters.
  • Nebula Research & Development's United Therapeutics position peaked at $1.62M in Q4 2024.
  • 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.